# OPtimizing REperfusion by Primary Intra-Arterial ThRomboLysis for Medium Vessel Occlusion

Study · id `cardio:ct-nct07137832` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07137832](<https://clinicaltrials.gov/study/NCT07137832>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07137832

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 530 participants.

## Technical summary

Registry record NCT07137832. Randomized; single masking; primary purpose treatment. Start 2025-10-09 (actual); primary completion 2028-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 530 participants (planned count; ClinicalTrials.gov record NCT07137832, source copy `cardio:ctgov-nct07137832-2026-08-24`, retrieved 2026-10-26)
- Started: 2025-10-09 (actual) (ClinicalTrials.gov record NCT07137832, source copy `cardio:ctgov-nct07137832-2026-08-24`, retrieved 2026-10-26)
- Primary completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT07137832, source copy `cardio:ctgov-nct07137832-2026-08-24`, retrieved 2026-10-26)
- Completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT07137832, source copy `cardio:ctgov-nct07137832-2026-08-24`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07137832, source copy `cardio:ctgov-nct07137832-2026-08-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07137832-2026-08-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: OPtimizing REperfusion by Primary Intra-Arterial ThRomboLysis for Medium Vessel Occlusion
- Acronym: PEARL-MeVO
- Condition: Acute Ischemic Stroke
- Intervention (Combination product): Primary intra-arterial thrombolysis
- Intervention (Other): Standard medical treatment
- Lead sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (`cardio:org-sun-yat-sen-memorial-hospital-of-sun-yat-sen-university`)

## Provenance

Content hash: b07a5bb98952d533ad11fe1597bbae9632a7bdc42c605a9036a88ac5aa1b8e28
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
